ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1262

Fish Oil Supplementation and Pro-inflammatory and Pro-Resolving Lipid Mediators in Patients with and Without Systemic Lupus Erythematosus
Abstract Number: 0836

Flare After Switching from Intravenous Tocilizumab to Subcutaneous Formulation in Patients with Rheumatoid Arthritis
Abstract Number: 1550

Flares and Side Effects After COVID-19 Vaccination in Patients with Rheumatic Diseases
Abstract Number: 0117

Flares Following Herpes Zoster Recombinant Zoster Vaccination Among Adults Age ≥50 Years with Immune Mediated Inflammatory Diseases in the United States
Abstract Number: 0698

Flow Cytometry and Sorting of Single Antibody Secreting Cells from Frozen Muscle Tissue
Abstract Number: 0644

Follow-up Scheduling Appears Essential for Success of Rheumatology High Blood Pressure Protocol Across Health Systems
Abstract Number: 1142

For Vulnerable Population Treated at a Community Health Center (CHC), Primary Care Physician (PCP) Turnover Should Be Included in Social Determinants of Health (SDH) on Non-completing Osteoporosis Treatment
Abstract Number: 1139

Fracture Liaison Service Outcomes at a Southern California County Hospital Highlights Need for Health System Improvements
Abstract Number: 1140

Fracture Risk in DXA-Appropriate Patients on Glucocorticoids: Is Everyone Tested According to Screening Guidelines?
Abstract Number: 1267

Frailty and Emergency Department Utilization in Systemic Lupus Erythematosus: An Administrative Claims Data Analysis
Abstract Number: 0078

Frequency and Clinical Characteristics of Secondary Antiphospholipid Syndrome in Systemic Lupus Erythematosus: The Georgia Lupus Registry
Abstract Number: 1210

Frequency of Anterior Atlanto-Axial Subluxation in Patients with Rheumatoid Arthritis
Abstract Number: 0483

Frequent Use of Prescription Oral NSAIDs Among People with Knee or Hip Osteoarthritis Despite Contraindications to or Precautions with NSAIDs
Abstract Number: 0542

Functional Characterization of Glycoprotein Nonmetastatic Melanoma Protein B in Scleroderma Fibrosis
Abstract Number: 0456

Functional Connectivity, Enhanced Blood-Brain Barrier Leakage and Cognitive Impairment in Systemic Lupus Erythematosus

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].